Medicine and Dentistry
Patient
100%
Human Immunodeficiency Virus
86%
COVID-19
55%
Antiretroviral Therapy
43%
Therapeutic Procedure
37%
Infection
24%
Diseases
23%
Combination Therapy
23%
RNA
22%
Severe Acute Respiratory Syndrome Coronavirus 2
21%
Follow up
19%
Predictor
18%
Analysis
17%
Inpatient
16%
Drug
15%
Chemotherapeutic Agent
15%
Incidence
15%
Age
12%
Nonnucleoside Reverse Transcriptase Inhibitor
11%
Proteinase Inhibitor
10%
Fatigue
10%
Plasma
10%
Cells
10%
Person
9%
Rheumatoid Arthritis
9%
Itraconazole
9%
Association
8%
Neutrophil
8%
Pneumonia
8%
Observational Study
8%
Synovitis
8%
Drive
8%
Muscle Function
7%
Human Immunodeficiency Virus 1
7%
Monocyte
7%
Base
7%
Hazard Ratio
6%
Highly Active Antiretroviral Therapy
6%
Progressive Multifocal Leukoencephalopathy
6%
Efavirenz
6%
Interleukin 10
6%
Cidofovir
6%
Relapse
6%
Systemic Lupus Erythematosus
6%
High Density Lipoprotein Cholesterol
6%
Monotherapy
6%
Granulocyte
6%
Self Rated Health
6%
Programmed Death-Ligand 1
6%
Diagnosis
6%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
91%
Drug
25%
Incidence
22%
Drug Resistance
17%
Diseases
17%
Prevalence
16%
Human Immunodeficiency Virus 1
14%
Nonnucleoside Reverse Transcriptase Inhibitor
14%
RNA
14%
Atazanavir Plus Ritonavir
13%
Infection
12%
Lamivudine
11%
Observational Study
10%
Proteinase Inhibitor
9%
Tuberculosis
9%
Human Immunodeficiency Virus Infection
9%
Atazanavir
9%
Emergency
9%
Toxicity
9%
Chemotherapy
8%
Efavirenz
8%
Dolutegravir
8%
Base
7%
Death
7%
RNA Directed DNA Polymerase Inhibitor
6%
Vinblastine
6%
Relapse
6%
Daclatasvir
6%
Glucose
6%
Asthma
6%
Lopinavir Plus Ritonavir
6%
High Density Lipoprotein Cholesterol
6%
Prospective Study
6%
SARS Coronavirus
6%
Adverse Event
6%
Non Communicable Disease
5%
Nevirapine
5%
Hepatitis C Virus
5%
Darunavir
5%
Nursing and Health Professions
Patient
49%
Antiretroviral Therapy
22%
Time
17%
Cohort Analysis
14%
Procedures
10%
Fatigue
9%
Toxicity
7%
Combination Therapy
7%
Control
7%
Treatment Failure
7%
Diseases
7%
Drug
7%
Death
6%
Interleukin 10
6%
Relapse
6%
Symptom
6%
Drug Concentration
6%
Measurement
6%
Dolutegravir
6%
Arterial Blood Gas
6%
Monoclonal Antibody
6%
Chimeric Antigen Receptor T-Cell
6%
C Reactive Protein
6%
Male
6%
Inpatient
6%
Supplementation
5%
Health Status
5%
Electric Potential
5%
Clinician
5%
Woman
5%
Proportional Hazards Model
5%
